COMP <GO>
ROIV vs GMAB // PIOTROSKI F-SCORE QUALITY
Roivant Sciences Ltd. (NASDAQ) VS. Genmab A/S ADS (NASDAQ) • 15-METRIC TALLY: ROIV 1
— GMAB 10
▲ PIOTROSKI F-SCORE QUALITY LEADER: GMAB
LAST: $37.52 (+1.11%) • MKT CAP: $27.10B
piotroski-score
3/9
LAST: $56.49 (-1.40%) • MKT CAP: $35.25B
piotroski-score
8/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ROIV VS. GMAB)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ROIV | GMAB | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -14.00% | 9.90% | -23.90 | GMAB | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 21.0x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.80% | 2.21% | -5.01 | GMAB | /fcf-yield <GO> |
| Operating Margin | -60.00% | 13.90% | -73.90 | GMAB | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 10.90% | -70.90 | GMAB | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | 22.00% | -87.00 | GMAB | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 3.74 | +22.26 | ROIV | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 3/9 | 8/9 | -5.00 | GMAB | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.2 | 85.2 | -28.00 | GMAB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 1.09 | -0.09 | GMAB | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.0x | 27.6x | +0.40 | GMAB | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $27.10B | $35.25B | -$8.15B | GMAB | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ROIV REV | GMAB REV | ROIV GROSS % | GMAB GROSS % | ROIV FCF | GMAB FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.3M | — | — | — | -$758.6M | — |
| FY 2024 | $29.1M | — | — | — | -$844.0M | — |
| FY 2023 | $32.7M | — | — | — | -$766.7M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ROIV // BETA 1.00
GMAB // BETA 1.09